Therapeutic effects of rhIL-11 on sepsis patients combined with thrombocytopenia

doi:10.3969/j.issn.1002-1949.2015.09.010

Abstract：Objective To observe the platelet recovering and anti -inflammatory effects of recombinant human interleukin -11 ( rhIL -11 ) on the patients with sepsis who combined with thrombocytopenia , and to explore its possible mechanism . Methods Eighty patients with sepsis combined with thrombocytopenia were divided into treatment group ( rhIL-11 group) and control group (conventional therapy group ) randomly. All the patients received active antibiotics and other comprehensive treatment .rhIL-11 group were given subcutaneous injection of rhIL -11 25 μg/( kg· d) additionally for 7 days.When the platelet counts increased to 100 ×109/L, the injection was discontinued.The peripheral platelet counts were observed on the first , third, fifth, seventh, and ninth day after the treatment.Inflammatory markers (LPS, TNF-α, CRP, PCT), the length of ICU stay, and 28-day mortality were compared between two groups .Results After the third day platelet count in rhIL-11 group was significantly higher than that in control group (P<0.05);PCT, LPS and TNF-αvalues of rhIL-11 group were lower than the conventional treatment group from the third day to the ninth day.Mortality of conventional treatment group within 28 days was significantly higher than that of rhIL -11 treatment group (27.5% vs 12.5%).There were no severe adverse event in rhIL -11 group. Conclusion RhIL-11 has a protective role and can accelerate recovery of platelets , and remarkably lessen the extent of inflammatory responses , hence reducing the mortality in sepsis patients accompanied with thrombocytopenia .